Patients with hypopituitarism from treatment for prior tumor (PA 88%, CP 12%). Patients with acromegaly or Cushing disease and those on GH replacement therapy were excluded. Deaths within 1 month of surgery were excluded. Here, GH1 is linked to neoplasm.